Preclinical Demonstrations of Synergistic Active Nutrient/Drug (and) Combination as a Potential Treatment for Malignant Pleural Mesothelioma

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Volta, Viviana ^a,d   Ranzato, Elia ^b   Martinotti, Simona ^b   Gallo, Simone ^a   Russo, Maria Veronica ^a   Mutti, Luciano ^c   Biffo, Stefano ^a,b   Burlando, Bruno ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Vercelli National Health Trust   (Italy)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; EPIGALLOCATECHIN GALLATE; GEMCITABINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR EXTRACT; TUMOR LYSATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CATECHIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ABDOMINAL BLEEDING; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NUTRIENT; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DRUG SCREENING; LUNG TUMOR; MESOTHELIOMA; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PLEURA TUMOR; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCORBIC ACID; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICE; MICE, INBRED NOD; MICE, SCID; PLEURAL NEOPLASMS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874621341     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058051     Document Type: Article

References (50)

1. Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, et al. (2006) Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 103: 14128-14133.
2. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, et al. (2007) A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 7: 147-154.
3. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, et al. (2009) Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer 124: 201-207.
4. West SD, Lee YC, (2006) Management of malignant pleural mesothelioma. Clin Chest Med 27: 335-354.
5. Sugarbaker DJ, Norberto JJ, (1998) Multimodality management of malignant pleural mesothelioma. Chest 113: 61S-65S.
6. Belli C, Fennell D, Giovannini M, Gaudino G, Mutti L, (2009) Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 14: 423-437.
7. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS, (2006) The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1: 591-601.
8. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889.
9. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, et al. (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35: 479-495.
10. Zauderer MG, Krug LM, (2011) The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol 12: 163-172.
11. Reagan-Shaw S, Nihal M, Ahsan H, Mukhtar H, Ahmad N, (2008) Combination of vitamin E and selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio. The Prostate 68: 1624-1634.
12. Constantinou C, Papas A, Constantinou AI, (2008) Vitamin E and cancer: An insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 123: 739-752.
13. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, et al. (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 105: 11105-11109.
14. Cameron E, Pauling L, (1978) Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75: 4538-4542.
15. Ranzato E, Biffo S, Burlando B, (2011) Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism. Am J Respir Cell Mol Biol 44: 108-117.
16. Martinotti S, Ranzato E, Burlando B, (2011) In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicology in Vitro 25(8): 1568-1574.
17. Kindler HL, van Meerbeeck JP, (2002) The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 29: 70-76.
18. Cooper R, Morre DJ, Morre DM, (2005) Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med 11: 521-528.
19. Yang CS, Wang X, Lu G, Picinich SC, (2009) Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 9: 429-439.
20. Li GX, Chen YK, Hou Z, Xiao H, Jin H, et al. (2010) Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis 31: 902-910.
21. Azam S, Hadi N, Khan NU, Hadi SM, (2004) Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties. Toxicol In Vitro 18: 555-561.
22. Ranzato E, Martinotti S, Magnelli V, Murer B, Biffo S, et al. (2012) Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2-dependent T-type Ca2+ channel opening. J Cell Mol Med 16: 2667-2678.
23. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, et al. (1994) Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 54: 2055-2059.
24. Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, et al. (1999) Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 13: 527-534.
25. Orecchia S, Schillaci F, Salvio M, Libener R, Betta PG, (2004) Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer 45(1): S37-43.
26. Maeda O, Usami N, Kondo M, Takahashi M, Goto H, et al. (2004) Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 23: 964-972.
27. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
28. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M, (2007) Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 104: 967-972.
29. Pepe MS, Fleming TR, (1989) Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics 45: 497-507.
30. Bertino P, Piccardi F, Porta C, Favoni R, Cilli M, et al. (2008) Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 14: 541-548.
31. Amoh Y, Nagakura C, Maitra A, Moossa AR, Katsuoka K, et al. (2006) Dual-color imaging of nascent angiogenesis and its inhibition in liver metastases of pancreatic cancer. Anticancer Res 26: 3237-3242.
32. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, et al. (2005) Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93: 319-330.
33. Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S, (2009) Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett 275: 86-92.
34. Isbrucker RA, Bausch J, Edwards JA, Wolz E, (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem Toxicol 44: 626-635.
35. Padayatty SJ, Levine M, (2000) Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 19: 423-425.
36. Verrax J, Calderon PB, (2009) Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47: 32-40.
37. Harris JE Jr, Shin J, Lee B, Pelosky K, Hooker CM, et al. (2011) A murine xenograft model of spontaneous metastases of human lung adenocarcinoma. J Surg Res 171(1): 75-79.
38. Dai J, Weinberg RS, Waxman S, Jing Y, (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277.
39. Grad JM, Cepero E, Boise LH, (2001) Mitochondria as targets for established and novel anti-cancer agents. Drug Resist Updat 4: 85-91.
40. Nagy B, Mucsi I, Molnar J, Thurzo L, (2002) Combined effect of cisplatin and 5-fluorouracil with irradiation on tumor cells in vitro. Anticancer Res 22: 135-138.
41. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, et al. (2011) Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50: 1610-1619.
42. Luo T, Wang J, Yin Y, Hua H, Jing J, et al. (2010) (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Canc Res 12: R8.
43. Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, et al. (2006) (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer research 66: 9260-9269.
44. Lang M, Henson R, Braconi C, Patel T, (2009) Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int 29: 670-677.
45. Mereles D, Hunstein W, (2011) Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises? Int J Mol Sci 12: 5592-5603.
46. Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, et al. (2005) A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 24: 269-276.
47. Wang LR, Huang MZ, Xu N, Shentu JZ, Liu J, et al. (2005) Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 6: 446-450.
48. Isbrucker RA, Bausch J, Edwards JA, Wolz E, (2006) Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem Toxicol 44: 626-635.
49. Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA, (2000) Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 7: 1421-1425.
50. Feng M, Zhang J, Anver M, Hassan R, Ho M, (2011) In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer 2: 123-131.